Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict ibrutinib success in tough leukemia

NCT ID NCT02827617

Knowledge-focused Sponsor: Oncology Institute of Southern Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 56 people with a high-risk form of chronic lymphocytic leukemia (CLL) who were taking the drug ibrutinib. Researchers looked for changes in the blood that could show early on whether the drug was working or failing. The goal is to find simple markers that help doctors make better treatment decisions for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ibrutinib
What this could lead to
If successful, this could help doctors identify early which patients benefit from ibrutinib and which might need a different treatment.
What could go wrong
This is a small, observational study that does not test a new treatment. The findings may not change practice without larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2016

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult CLL patients harboring TP53 genetic abnormalities, independent of whether treatment naïve or previously treated, who warrants treatment according to iwCLL 2008 criteria, and who is planned to receive ibrutinib at standard dose as per clinical practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female adults 18 years or older * Documented diagnosis of CLL, according to iwCLL 2008 criteria * Presence of TP53 mutation as demonstrated by sequencing at the local laboratory and/or presence of 17p deletion as demonstrated by fluorescence in situ hybridization (FISH) testing performed at the local laboratory * CLL that warrants treatment * Planned treatment with ibrutinib 420 mg quaque die * Willing and able to comply with scheduled visits, laboratory tests, and study procedures * Evidence of a signed informed consent Exclusion Criteria: * Current or prior histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation). * Prior treatment with ibrutinib or idelalisib

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia

Contacts and locations

Locations

  • Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi"

    Udine, 33100, Italy

  • Clinica Luganese Moncucco

    Lugano, 6903, Switzerland

  • Department of Haematology, Tor Vergata Hospital

    Rome, 00133, Italy

  • Department of Medical and Surgical Sciences, section of Hematology

    Modena, 41124, Italy

  • Dipartimento di Ematologia, Niguarda Cancer Center, Ospedale Niguarda

    Milan, 20133, Italy

  • Division of Hematology, Department of Internal Medicine, Basel University Hospital

    Basel, 4031, Switzerland

  • Divisione di Ematologia, Universita' del Piemonte Orientale

    Novara, 28100, Italy

  • Ematologia, Ospedale di Circolo e Fondazione Macchi

    Varese, 21100, Italy

  • Hematology, Luzern Kantonsspital

    Lucerne, 6000, Switzerland

  • Institute of Hematology, Catholic University S. Cuore

    Roma, 00168, Italy

  • Onco Ematologia Clinico Sperimentale, I.R.C.C.S. Centro di Riferimento Oncologico

    Aviano, 33081, Italy

  • Oncology Institute of Southern Switzerland

    Bellinzona, Switzerland, 6500, Switzerland

  • Ospedale San Raffaele

    Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.